.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Chubb
Johnson and Johnson
Teva
Cantor Fitzgerald
Accenture
Chinese Patent Office
Express Scripts
Moodys
Covington

Generated: September 22, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Summary for Patent: ► Subscribe

Title:Human antibodies and antibody-drug conjugates against CD74
Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.
Inventor(s): Verploegen; Sandra (Nieuwegein, NL), Overdijk; Marije (Utrecht, NL), Dijkhuizen; Riemke Van (Zeist, NL), Bleeker; Willem Karel (Amsterdam, NL), Van Berkel; Patrick (Utrecht, NL), Parren; Paul (Odijk, NL), Lisby; Steen (Frederiksberg, DK)
Assignee: GENMAB A/S (Copenhagen, DK)
Application Number:13/982,959
Patent Claims:1. An antibody which binds to CD74 variants 1 and 2 and comprises a V.sub.L region comprising the CDR1, 2 and 3 sequences set forth in SEQ ID NO:24, SEQ ID NO:27, and SEQ ID NO:25, respectively, and a) a V.sub.H region comprising the CDR1, 2 and 3 sequences set forth in SEQ ID NO: 20, 21 and 22, respectively; b) a V.sub.H region comprising the CDR1, 2 and 3 sequences set forth in SEQ ID NOS:8, 9 and 10, respectively; c) a V.sub.H region comprising the CDR1, 2 and 3 sequences set forth in SEQ ID NO: 12, 13 and 14, respectively; or d) a V.sub.H region comprising the CDR1, 2 and 3 sequences set forth in SEQ ID NO: 16, 17 and 18, respectively.

2. The antibody of claim 1, which (a) binds to the extracellular domain of CD74 variant 1 with an EC.sub.50 of less than about 500 ng/mL; (b) binds to the extracellular domain of CD74 variant 2 with an EC.sub.50 of less than about 400 ng/mL; or (c) both of (a) and (b), when determined by enzyme-linked immunosorbent assay.

3. The antibody of claim 1, which binds to CD74 on Raji cells with an EC.sub.50 of less than about 400 ng/mL when determined by enzyme-linked immunosorbent assay.

4. The antibody of claim 1, which binds to cynomolgous CD74.

5. The antibody of claim 1, which is internalized after binding to CD74 expressed on the surface of a cell.

6. The antibody of claim 5, wherein the cell is a Raji cell.

7. The antibody of claim 1, which has an EC.sub.50 of less than about 60 ng/mL in inducing killing of Raji cells in an anti-kappa ETA assay.

8. The antibody of claim 1, which has an off-rate at 0.degree. C. of 0.02 to 1.0 min.sup.-1.

9. The antibody of claim 1, which is a human monoclonal antibody.

10. The antibody of claim 1, which has an isotype selected from IgG1 and IgG4.

11. An antibody of claim 1, which is conjugated to a therapeutic moiety.

12. The antibody of claim 11, which is conjugated to the therapeutic moiety via a linker attached to sulphydryl residues in the antibody, obtained by at least partial reduction of the antibody.

13. The antibody of claim 11, wherein the therapeutic moiety is a cytotoxic moiety, a radioisotope, a chemotherapeutic agent, a lytic peptide or a cytokine.

14. The antibody of claim 13, which is conjugated to a cytotoxic moiety.

15. The antibody of claim 14, wherein the cytotoxic moiety is selected from the group consisting of taxol; cytochalasin B; gramicidin D; ethidium bromide; emetine; mitomycin; etoposide; tenoposide; vincristine; vinblastine; colchicin; doxorubicin; daunorubicin; dihydroxy anthracin dione; maytansine or an analog or derivative thereof; an auristatin or a functional peptide analog or derivative thereof; dolastatin 10 or 15 or an analogue thereof; irinotecan or an analogue thereof; mitoxantrone; mithramycin; actinomycin D; 1-dehydrotestosterone; a glucocorticoid; procaine; tetracaine; lidocaine; propranolol; puromycin; calicheamicin or an analog or derivative thereof; an antimetabolite; 6 mercaptopurine; 6 thioguanine; cytarabine; fludarabin; 5 fluorouracil; decarbazine; hydroxyurea; asparaginase; gemcitabine; cladribine; an alkylating agent; a platinum derivative; duocarmycin A; duocarmycin SA; rachelmycin (CC-1065) or an analog or derivative thereof; an antibiotic; pyrrolo[2,1-c][1,4]-benzodiazepines (PDB); diphtheria toxin; ricin toxin; cholera toxin; a Shiga-like toxin; LT toxin; C3 toxin; Shiga toxin; pertussis toxin; tetanus toxin; soybean Bowman-Birk protease inhibitor; Pseudomonas exotoxin; alorin; saporin; modeccin; gelanin; abrin A chain; modeccin A chain; alpha-sarcin; Aleurites fordii proteins; dianthin proteins; Phytolacca americana proteins; momordica charantia inhibitor; curcin; crotin; sapaonaria officinalis inhibitor; gelonin; mitogellin; restrictocin; phenomycin; enomycin toxins; ribonuclease (RNase); DNase I; Staphylococcal enterotoxin A; pokeweed antiviral protein; diphtherin toxin; and Pseudomonas endotoxin.

16. The antibody of claim 14, wherein the cytotoxic moiety is selected from the group consisting of an anthracycline, a pyrrolo[2,1-c][1,4]-benzodiazepine, maytansine, calicheamicin, duocarmycin, rachelmycin (CC-1065), dolastatin 10 or 15, irinotecan, or from an analog, derivative, or prodrug of any thereof.

17. The antibody of claim 14, wherein the cytotoxic moiety is an auristatin or a functional peptide analog or derivate thereof.

18. The antibody of claim 11, which has an IC.sub.50 of less than about 0.5 .mu.g/mL in inducing killing of Raji, Daudi or M4A4 cells, when determined after incubating the Raji, Daudi or M4A4 cells with an anti-CD74 antibody-drug conjugate for three days and staining for viable cells with AlamarBlue.

19. The antibody of claim 13, which is conjugated to a cytokine selected from the group consisting of IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, IL-24, IL-27, IL-28a, IL-28b, IL-29, KGF, IFN.alpha., IFN.beta., IFN.gamma., GM-CSF, CD40L, Flt3 ligand, stem cell factor, ancestim, and TNF.alpha..

20. A recombinant eukaryotic or prokaryotic host cell which produces the antibody of claim 1.

21. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

22. A method of treating cancer comprising administering to a subject in need thereof an antibody according to claim 1.

23. A method of reducing the risk of cancer progression or reducing the risk of recurrence of a cancer in remission in a subject comprising administering to the subject an antibody according to claim 1.

24. The method of claim 22, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, endometrial/cervical cancer, gastric cancer, head and neck cancer, lung cancer, malignant glioma, malignant melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, liver cancer, thymus cancer, malignant fibrous histiosarcoma, acoustic schwannoma, pituitary adenoma, and an adenoma.

25. The method of claim 22, wherein the cancer is selected from the group consisting of malignant lymphoma, B cell chronic lymphocytic leukemia (B-CLL), chronic myeloid leukemia (CML) in blast phase, non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), monocytiod B cell lymphoma (MBCL), hairy-cell leukemia (HCL), and T cell lymphoma.

26. The method of claim 25, wherein the cancer is NHL.

27. The method of claim 25, wherein the cancer is MM.

28. The method of claim 24, wherein the cancer is ovarian cancer.

29. The method of claim 24, wherein the cancer is breast cancer.

30. The method of claim 24, wherein the cancer is pancreatic cancer.

31. The method of claim 24, wherein the cancer is selected from the group consisting of prostate cancer, gastric cancer, and colorectal cancer.

32. The method of claim 22, wherein at least one further therapeutic agent is administered.

33. The method of claim 32, wherein the at least one further therapeutic agent is selected from the group consisting of a second antibody or ADC; a chemotherapeutic agent; an inhibitor of angiogenesis, neovascularization, and/or other vascularization; an anti-cancer immunogen; a cytokine or chemokine; a cell cycle control or apoptosis regulator; a hormonal regulating agent; an anti-anergic agent; a virus or viral proteins; immune system cells; a differentiation inducing agent; -IFN-.gamma.; an anti-inflammatory, immunosuppressive and/or immunomodulatory agent; and a combination of any thereof.

34. The method of claim 33, wherein the at least one therapeutic agent is selected from the group consisting of a CD20-specific antibody, a CD138-specific antibody, a CD38-specific antibody, an anti-VEGF-A antibody, melphalanan, lenalidomide, bortezomib, fluorouracil, gemticabine, irinotecan, cisplatin, and a derivative or analog thereof.

35. A method of treating an autoimmune disease comprising administering to a subject in need thereof an antibody according to claim 1.

36. A method for inducing cell death, inhibiting growth, and/or inhibiting proliferation of a cell expressing CD74 , comprising contacting the cell with the antibody of claim 1.

37. An antibody which binds to CD74 variants 1 and 2 and comprises: (a) a V.sub.H region comprising the sequence of SEQ ID NO: 19 and a V.sub.L region comprising the sequence of SEQ ID NO: 26; (b) a V.sub.H region comprising the sequence of SEQ ID NO: 7 and a V.sub.L region comprising the sequence of SEQ ID NO: 26; (c) a V.sub.H region comprising the sequence of SEQ ID NO: 7 and a V.sub.L region comprising the sequence of SEQ ID NO: 23; (d) a V.sub.H region comprising the sequence of SEQ ID NO: 11 and a V.sub.L region comprising the sequence of SEQ ID NO: 26; or (d) a V.sub.H region comprising the sequence of SEQ ID NO: 15 and a V.sub.L region comprising the sequence of SEQ ID NO: 26.

38. An anti-idiotypic antibody against the antibody of claim 37.

39. A multispecific antibody, comprising a first antigen-binding region of an antibody selected from the group consisting of: (a) an antibody comprising a VH region comprising the sequence of SEQ ID NO:19 and a VL region comprising the sequence of SEQ ID NO:26; (b) an antibody comprising a VH region comprising the sequence of SEQ ID NO:7 and a VL region comprising the sequence of SEQ ID NO:23; (c) an antibody comprising a VH region comprising the sequence of SEQ ID NO:11 and a VL region comprising the sequence of SEQ ID NO:26; and (d) an antibody comprising a VH region comprising the sequence of SEQ ID NO:15 and a VL region comprising the sequence of SEQ ID NO:26, and at least one second antigen-binding region having a different binding specificity.

40. The antibody of claim 39, which is a bispecific antibody.

41. The antibody of claim 39, which is a bispecific antibody wherein the first antigen-binding region is linked to a first Fc-region having an amino acid substitution at a position selected from the group consisting of 366, 368, 370, 399, 405, 407 and 409, and the second antigen-binding region is linked to a second Fc-region having an amino acid substitution at a position selected from the group consisting of 366, 368, 370, 399, 405, 407 and 409, and the first and second Fc-regions are not substituted in the same positions.

42. An expression vector comprising a nucleotide sequence encoding one or more of the amino acid sequences selected from the group consisting of SEQ ID NOs: 7, 11, 15, 19, and 23, or any combination thereof.

43. An expression vector according to claim 42, further comprising a nucleotide sequence encoding the constant region of a human antibody light chain, of a human antibody heavy chain, or both.

Summary for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Denmark2011 00064Feb 1, 2011
PCT Information
PCT FiledFebruary 01, 2012PCT Application Number:PCT/EP2012/051679
PCT Publication Date:August 09, 2012PCT Publication Number: WO2012/104344

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Inventors Patent Expiration Status Orphan Source
Merck
ELSPAR
asparaginase
VIAL1010630011978-01-10► Subscribe GENMAB A/S (Copenhagen, DK) Verploegen; Sandra (Nieuwegein, NL), Overdijk; Marije (Utrecht, NL), Dijkhuizen; Riemke Van (Zeist, NL), Bleeker; Willem Karel (Amsterdam, NL), Van Berkel; Patrick (Utrecht, NL), Parren; Paul (Odijk, NL), Lisby; Steen (Frederiksberg, DK) ► SubscribeRXsearch
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: ► Subscribe

Country Document Number Publication Date
Australia2012213437Aug 18, 2016
Australia2012213437May 02, 2013
Canada2826186Aug 09, 2012
China103458930Dec 18, 2013
European Patent Office2670440Dec 11, 2013
Israel227477Sep 30, 2013
Japan2014507138Mar 27, 2014
Mexico2013008832Sep 06, 2013
Russian Federation2013140433Mar 10, 2015
Singapore10201608138RNov 29, 2016
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.


« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

QuintilesIMS
Argus Health
Boehringer Ingelheim
Fish and Richardson
UBS
Express Scripts
Merck
Teva
Julphar
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot